• / Free eNewsletters & Magazine
  • / My Account

JASDAQ

  1. R-Tech Ueno: Announcement on Completion of the Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

    R-Tech Ueno: Announcement on Completion of the Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096

  2. R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

    R-Tech Ueno: Announcement on Collaborative Development of Therapeutic Agent for Diabetic Retinopathy and Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) with Hokkaido University

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.